Maxim Group set a $9.00 target price on Brainstorm Cell Therapeutics (NASDAQ:BCLI) in a report issued on Thursday morning. The brokerage currently has a buy rating on the biotechnology company’s stock.
Separately, ValuEngine lowered Brainstorm Cell Therapeutics from a hold rating to a sell rating in a research note on Thursday, December 21st.
Brainstorm Cell Therapeutics (NASDAQ:BCLI) opened at $3.41 on Thursday. Brainstorm Cell Therapeutics has a 12 month low of $2.88 and a 12 month high of $5.18.
A number of institutional investors and hedge funds have recently modified their holdings of BCLI. Clearline Capital LP acquired a new position in Brainstorm Cell Therapeutics in the fourth quarter valued at approximately $208,000. Deutsche Bank AG lifted its stake in Brainstorm Cell Therapeutics by 330.0% in the fourth quarter. Deutsche Bank AG now owns 98,590 shares of the biotechnology company’s stock valued at $386,000 after buying an additional 75,664 shares during the period. Renaissance Technologies LLC lifted its stake in Brainstorm Cell Therapeutics by 396.9% in the fourth quarter. Renaissance Technologies LLC now owns 114,550 shares of the biotechnology company’s stock valued at $449,000 after buying an additional 91,495 shares during the period. Finally, Vanguard Group Inc. lifted its stake in Brainstorm Cell Therapeutics by 2.8% in the second quarter. Vanguard Group Inc. now owns 657,101 shares of the biotechnology company’s stock valued at $2,733,000 after buying an additional 17,657 shares during the period. 9.72% of the stock is currently owned by hedge funds and other institutional investors.
COPYRIGHT VIOLATION WARNING: “Brainstorm Cell Therapeutics (BCLI) Given a $9.00 Price Target by Maxim Group Analysts” was reported by Markets Daily and is the property of of Markets Daily. If you are accessing this article on another publication, it was copied illegally and republished in violation of US and international copyright and trademark legislation. The legal version of this article can be viewed at https://www.themarketsdaily.com/2018/03/11/brainstorm-cell-therapeutics-bcli-given-a-9-00-price-target-by-maxim-group-analysts.html.
About Brainstorm Cell Therapeutics
Brainstorm Cell Therapeutics Inc is a biotechnology company. The Company is engaged in developing adult stem cell therapies for debilitating neurodegenerative disorders, such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig’s disease), Multiple Sclerosis (MS) and Parkinson’s disease (PD), among others.
Receive News & Ratings for Brainstorm Cell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brainstorm Cell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.